Search results
These are lupus anticoagulant (LA), anticardiolipin antibodies (aCL) and anti-beta-2 glycoprotein I antibodies (anti-B2GPI). This review will focus on anti-B2PI and their role in APS in terms of their relationship to the putative pathogenesis of the disorder and their clinical associations.
- The role of beta-2-glycoprotein I in health and disease associating ...
Beta-2-Glycoprotein I (β2GPI) plays a number of essential...
- The role of beta-2-glycoprotein I in health and disease associating ...
14 paź 2021 · Anti-β-2 glycoprotein I antibodies (anti-B2GPI) are often cited as the major pathogenically relevant antibody in antiphospholipid syndrome (APS), but it is unclear if there is clinical evidence to support this theory.
Beta-2-Glycoprotein I (β2GPI) plays a number of essential roles throughout the body. β2GPI, C-reactive protein and thrombomodulin are the only three proteins that possess the dual capability to up and down regulate the complement and coagulation systems depending upon external stimulus.
1 sie 2019 · Recent advances allow us to propose antibodies targeting beta-2-glycoprotein I (β 2 -GPI) as the most specific antibodies associated with anti-phospholipid syndrome (APS). Therefore, there is now a crucial need for powerful biological assays to adequately monitor them.
12 lip 2012 · In this overview, we will summarize our knowledge on the etiology of the autoantibodies, and we will discuss the evidence that identify autoantibodies against β 2 -glycoprotein I as the culprit of APS. Topics: autoantibodies, glycoprotein, antiphospholipid antibodies, antibodies, thrombosis, thrombus, phospholipids.
4 lis 2021 · Effects of beta 2-glycoprotein 1 antibodies on different cellular targets and their damage-generating pathways (A) aß2GP1 pro-inflammatory effect via TLR4/Myd88. (B) aß2GP1 induced a reduction in the promigratory effect of IL6 and STAT3.
In this review we discuss the characteristics of β(2)GPI; the generation, pathogenic effects, and standardized testing of anti-β(2)GPI antibodies; and the potential use of therapies that target the β(2)GPI/anti-β(2)GPI interaction in the treatment of APS.
